Best Biotech News Sources: Legend LB2501 Data
Decision brief
Answer first · skim in under a minute
Legend Biotech shares soared over 40% after disclosing early in vivo CAR-T data in Non-Hodgkin's lymphoma. This analysis explains the development, implications for pharma teams, and key milestones to track.
Legend Biotech disclosed Phase 1 in vivo CAR-T data for LB2501 in relapsed/refractory non-Hodgkin lymphoma around EHA 2026. For readers ranking the best biotech news sources, the durable path is primary wires, ClinicalTrials.gov, and FDA product-class pages—not social amplification of early ORR figures.
Contents10 sections
Key Takeaways
- At dose level 2, Legend reported 100% ORR (6/6) and 83.3% CR (5/6) after a single LB2501 infusion without lymphodepletion.
- Twelve patients were treated across DL1 and DL2 (n=6 each); median prior lines were three; 58.3% were refractory to last therapy.
- Company safety summary: no DLTs, no SAEs, no ICANS, and no deaths in the disclosed cohort.
- Trial ID: NCT07002112. These are early Phase 1 signals—not confirmatory efficacy.
What did Legend announce for LB2501?
On June 2, 2026, Legend Biotech USA said it would present late-breaking Phase 1 data for LB2501 at EHA 2026. The program is a CD19/CD20 dual-targeting in vivo CAR-T designed as an off-the-shelf, single-infusion approach for B-cell malignancies.
Follow-on GlobeNewswire releases dated June 14–15, 2026 framed the readout as clinical proof-of-concept in relapsed/refractory B-cell NHL (abstract #LB5006).
Wire: Legend EHA 2026 late-breaker (GlobeNewswire).
Which efficacy and safety numbers are in the primary release?
At DL2, Legend reported ORR of 100% (6/6) and CR of 83.3% (5/6), with all responses ongoing at cutoff. Across the disclosed Phase 1 cohort, 12 patients with R/R B-NHL received LB2501 (DL1 n=6; DL2 n=6).
Patients had a median of three prior lines. About 58.3% were refractory to their most recent treatment. The study used a single intravenous infusion without lymphodepleting chemotherapy.
Safety language in the wire: no dose-limiting toxicities, no serious adverse events, no ICANS, and no deaths reported in that disclosure window.
Primary: LB2501 proof-of-concept release (GlobeNewswire).
Where is the trial registered?
Legend cites ClinicalTrials.gov study NCT07002112 for the open-label Phase 1 evaluation of the CD19/CD20 dual-target in vivo CAR-T lentiviral product in relapsed/refractory B-cell malignancies.
Registry pages let BD and diligence teams check status, eligibility, and sites without relying on conference social posts.
Registry: NCT07002112 on ClinicalTrials.gov.
How do SEC exhibits help fact-check conference claims?
Legend also filed abstract-style exhibit materials on EDGAR describing the first-in-human Phase 1 design (NCT07002112), 3+3 escalation with backfilling, and single-infusion dosing without lymphodepletion.
Those exhibits restated the DL2 100% ORR and 83.3% CR figures and the “no DLT / no ICANS” safety framing. SEC exhibits are useful when conference slides circulate without a durable URL.
Filing: Legend SEC exhibit (exh_992.htm).
Why in vivo CAR-T changes deal and ops questions
Approved autologous CAR-T products require ex vivo manufacturing and typically lymphodepletion. An in vivo vector that generates CAR-T cells inside the patient could cut vein-to-vein time and center capacity needs if later trials confirm the early signal.
FDA’s cellular and gene therapy pages remain the baseline for product-class expectations on CMC, long-term follow-up, and safety monitoring—even when a sponsor markets an “off-the-shelf” narrative.
Regulator context: FDA cellular and gene therapy products.
What remains unproven after EHA 2026
The DL2 cohort is six patients. Durability past the disclosed cutoff, dose expansion, and comparison with approved CD19 CAR-T products are not established in these releases.
Market-moving price stories that circulate alongside the readout are not substitutes for ORR/CR tables. Prefer GlobeNewswire, EDGAR, and NCT07002112 when ranking the best biotech news sources for this catalyst.
Until dose-expansion and longer follow-up appear in a peer-reviewed venue or a larger company update, treat the 2026 EHA late-breaker as a hypothesis-generating Phase 1 signal for BD diligence, not a label-ready efficacy package.
Related NovaPharma coverage
- GSK’s Blenrep returns to the US market
- Eli Lilly pipeline and deals: GLP-1 and vaccines
- FDA gene therapy guidance for BD teams
Frequently Asked Questions
What did Legend report for LB2501 at EHA 2026?
In an ongoing Phase 1 study, dose level 2 showed a 100% objective response rate (6/6) and an 83.3% complete response rate (5/6) in relapsed/refractory non-Hodgkin lymphoma, with responses ongoing at data cutoff per company disclosures.
What is the NCT number for the LB2501 Phase 1 trial?
Legend identifies the open-label Phase 1 study as NCT07002112 on ClinicalTrials.gov, evaluating LB2501 in relapsed/refractory B-cell malignancies.
How should readers verify best biotech news sources on this story?
Start with Legend’s GlobeNewswire releases, the SEC exhibit filing that carries the abstract text, ClinicalTrials.gov NCT07002112, and FDA pages on cellular and gene therapy products—not secondary headlines alone.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CAR-T therapy.
Unlock full calendar →Legend Biotech pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
